ClinicalTrials.gg
CompletedNCT00562354Updated Nov 11, 2011Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years

A Phase 3 interventional study of 13vPnC in Healthy, sponsored by Pfizer. Completed at 2 sites in Japan. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-11.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
271
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate (13vPnC) vaccine in healthy Japanese adults aged >= 50 years.

02

Conditions studied

  • Healthy

Keywords

  • Vaccines, Pneumococcal Conjugate Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese descent male and female adults who do not have the potential to bear children >= 50 years of age.
  • Determined to be eligible for the study based on medical history, physical examination, and clinical judgment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of study vaccine, are eligible.
  • Sexually active men must agree and commit to use a medically accepted form of during the study and for at least 3 months after vaccination.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine.
  • Receipt of any vaccine within 30 days before study vaccination, except influenza vaccine.
  • Documented S pneumoniae infection within the past 5 years before study vaccination.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
271 participants (actual)

Study arms

  • Experimental
    1

    Stratum 1: \>= 65 years of age

    Biological: 13vPnC

  • Experimental
    2

    Stratum 2: 50 to 64 years of age

    Biological: 13vPnC

Interventions

  • Biological13vPnC

    13vPnC for both stratum

06

What researchers measure

Primary outcomes

  1. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population

    Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% confidence intervals (CIs) on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: 1 month after vaccination

  2. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: 1 month after vaccination

  3. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Overall Population

    Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: Prevaccination (Day 1), 1 month after vaccination

  4. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: Prevaccination (Day 1), 1 month after vaccination

Secondary outcomes

  1. Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination by Age Group

    Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: 1 month after vaccination

  2. Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Overall Population

    For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  3. Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  4. Comparison of Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination by Age Group

    For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  5. Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population

    For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  6. Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  7. Comparison of Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group

    For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  8. Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population

    For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  9. Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  10. Comparison of Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group

    For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: 1 month after vaccination

  11. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Overall Population

    Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: 1 month after vaccination

  12. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: 1 month after vaccination

  13. Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination by Age Group

    Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: 1 month after vaccination

  14. Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Overall Population

    Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: 1 month after vaccination

  15. Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: 1 month after vaccination

  16. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Overall Population

    Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).

    Time frame: Day 1 through 14

  17. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).

    Time frame: Day 1 through 14

  18. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Overall Population

    Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.

    Time frame: Day 1 through 14

  19. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

    Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.

    Time frame: Day 1 through 14

07

Results

Posted Nov 11, 2011

Participant flow

Participant flow — Overall Study
Milestone13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Started134137
Received study treatment134136
Evaluable immunogenicity population134134
Completed134135
Not completed02
Withdrew: Physician decision01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population

Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% confidence intervals (CIs) on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population
titer13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 1124 (101.5 to 150.7)
Serotype 362 (53.1 to 73.4)
Serotype 41333 (1054.4 to 1684.2)
Serotype 5215 (172.0 to 269.2)
Serotype 6A2256 (1884.4 to 2700.3)
Serotype 6B2861 (2406.4 to 3401.1)
Serotype 7F1793 (1476.1 to 2177.7)
Serotype 9V863 (652.9 to 1141.5)
Serotype 141494 (1267.1 to 1761.9)
Serotype 18C2082 (1683.5 to 2575.0)
Serotype 19A874 (729.0 to 1047.8)
Serotype 19F821 (655.7 to 1027.8)
Serotype 23F538 (415.9 to 696.7)
PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
titer13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 193 (70.3 to 124.2)162 (124.0 to 212.6)
Serotype 353 (42.0 to 67.8)73 (58.6 to 90.9)
Serotype 41209 (830.1 to 1762.2)1464 (1098.8 to 1950.9)
Serotype 5159 (113.6 to 221.2)289 (214.7 to 387.9)
Serotype 6A1667 (1283.1 to 2165.9)3082 (2431.0 to 3908.2)
Serotype 6B2556 (1967.1 to 3320.8)3182 (2527.6 to 4004.7)
Serotype 7F1469 (1075.6 to 2005.6)2218 (1772.6 to 2776.3)
Serotype 9V738 (497.8 to 1094.8)1007 (675.2 to 1501.7)
Serotype 141294 (1027.3 to 1629.2)1726 (1362.8 to 2185.2)
Serotype 18C1503 (1087.0 to 2078.8)2862 (2187.0 to 3745.6)
Serotype 19A616 (488.1 to 776.7)1241 (949.3 to 1621.7)
Serotype 19F614 (438.9 to 858.0)1083 (804.7 to 1458.5)
Serotype 23F361 (243.9 to 533.2)788 (566.6 to 1097.2)
PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Overall Population

Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
Prevaccination (Day 1), 1 month after vaccination
Reported as:
Geometric mean · fold rise
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Overall Population
fold rise13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 123.3 (19.17 to 28.31)
Serotype 311.5 (9.69 to 13.67)
Serotype 479.6 (55.79 to 113.47)
Serotype 542.4 (33.64 to 53.51)
Serotype 6A48.8 (35.04 to 67.87)
Serotype 6B16.6 (11.79 to 23.51)
Serotype 7F137.2 (99.26 to 189.69)
Serotype 9V13.4 (9.17 to 19.46)
Serotype 1412.4 (9.23 to 16.76)
Serotype 18C52.9 (38.41 to 72.82)
Serotype 19A41.9 (32.46 to 54.22)
Serotype 19F42.7 (32.34 to 56.25)
Serotype 23F47.5 (35.23 to 63.92)
PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
Prevaccination (Day 1), 1 month after vaccination
Reported as:
Geometric mean · fold rise
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
fold rise13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 118.7 (14.02 to 24.91)28.8 (22.17 to 37.52)
Serotype 39.8 (7.62 to 12.49)13.6 (10.66 to 17.24)
Serotype 450.7 (29.40 to 87.32)123.3 (78.54 to 193.67)
Serotype 534.3 (24.61 to 47.90)52.0 (37.59 to 71.88)
Serotype 6A32.3 (20.50 to 50.81)74.7 (46.39 to 120.22)
Serotype 6B11.2 (6.98 to 18.09)24.1 (14.68 to 39.60)
Serotype 7F99.9 (62.24 to 160.40)192.5 (124.26 to 298.35)
Serotype 9V7.3 (4.42 to 12.02)24.2 (14.02 to 41.86)
Serotype 1410.6 (7.00 to 16.08)14.6 (9.46 to 22.44)
Serotype 18C31.0 (19.68 to 48.75)89.2 (57.54 to 138.25)
Serotype 19A25.3 (18.75 to 34.13)69.5 (46.56 to 103.89)
Serotype 19F25.3 (17.42 to 36.65)70.3 (47.39 to 104.14)
Serotype 23F40.8 (26.53 to 62.89)54.7 (36.11 to 82.94)
SecondaryComparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination by Age Group

Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination by Age Group
titer13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 193 (70.3 to 124.2)164 (125.1 to 213.9)
Serotype 354 (42.2 to 67.9)73 (58.6 to 90.2)
Serotype 41331 (967.6 to 1831.7)1786 (1390.9 to 2293.9)
Serotype 5171 (123.9 to 236.4)294 (219.9 to 393.0)
Serotype 6A1663 (1287.0 to 2147.9)3148 (2502.2 to 3960.6)
Serotype 6B2462 (1905.0 to 3181.7)3383 (2721.3 to 4204.8)
Serotype 7F1484 (1097.7 to 2005.3)2247 (1818.6 to 2776.7)
Serotype 9V797 (557.1 to 1138.9)1062 (735.5 to 1533.7)
Serotype 141289 (1033.8 to 1608.1)1740 (1386.0 to 2183.8)
Serotype 18C1530 (1114.5 to 2099.8)2922 (2243.8 to 3804.0)
Serotype 19A604 (483.8 to 754.4)1267 (979.8 to 1637.9)
Serotype 19F627 (454.7 to 863.7)1094 (814.1 to 1470.4)
Serotype 23F398 (276.1 to 575.1)824 (596.3 to 1137.5)
Statistical analysis
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.6 · 95% CI 0.39 to 0.84Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.7 · 95% CI 0.54 to 1.01Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.7 · 95% CI 0.50 to 1.11Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.6 · 95% CI 0.38 to 0.90Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.5 · 95% CI 0.37 to 0.74Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.7 · 95% CI 0.52 to 1.02Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.7 · 95% CI 0.46 to 0.95Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.7 · 95% CI 0.45 to 1.25Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.7 · 95% CI 0.54 to 1.02Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.5 · 95% CI 0.35 to 0.79Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.5 · 95% CI 0.34 to 0.67Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.6 · 95% CI 0.37 to 0.88Confidence intervals for the ratio are back transformation of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean titer: 0.5 · 95% CI 0.30 to 0.79Ratio of GMTs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
SecondaryPercentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Overall Population

For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Overall Population
percentage of participants13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 191.6 (87.6 to 94.7)
Serotype 389.8 (85.6 to 93.2)
Serotype 495.2 (91.8 to 97.5)
Serotype 588.6 (84.0 to 92.2)
Serotype 6A98.5 (96.2 to 99.6)
Serotype 6B98.5 (96.2 to 99.6)
Serotype 7F96.5 (93.5 to 98.4)
Serotype 9V89.1 (84.7 to 92.5)
Serotype 1498.5 (96.2 to 99.6)
Serotype 18C96.6 (93.7 to 98.4)
Serotype 19A98.9 (96.7 to 99.8)
Serotype 19F94.2 (90.6 to 96.7)
Serotype 23F89.2 (84.8 to 92.7)
SecondaryPercentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 189.1 (82.5 to 93.9)94.0 (88.6 to 97.4)
Serotype 387.9 (81.1 to 92.9)91.8 (85.8 to 95.8)
Serotype 493.5 (87.6 to 97.2)96.9 (92.3 to 99.1)
Serotype 585.8 (78.5 to 91.4)91.3 (85.0 to 95.6)
Serotype 6A97.7 (93.5 to 99.5)99.2 (95.9 to 100.0)
Serotype 6B97.7 (93.4 to 99.5)99.3 (95.9 to 100.0)
Serotype 7F93.9 (88.4 to 97.3)99.2 (95.7 to 100.0)
Serotype 9V88.6 (82.0 to 93.5)89.5 (83.0 to 94.1)
Serotype 1498.5 (94.6 to 99.8)98.5 (94.6 to 99.8)
Serotype 18C95.5 (90.4 to 98.3)97.7 (93.5 to 99.5)
Serotype 19A99.2 (95.8 to 100.0)98.5 (94.6 to 99.8)
Serotype 19F93.0 (87.1 to 96.7)95.3 (90.2 to 98.3)
Serotype 23F86.2 (79.0 to 91.6)92.3 (86.3 to 96.2)
SecondaryComparison of Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination by Age Group

For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Comparison of Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination by Age Group
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 189.1 (82.5 to 93.9)94.0 (88.6 to 97.4)
Serotype 387.9 (81.1 to 92.9)91.8 (85.8 to 95.8)
Serotype 493.5 (87.6 to 97.2)96.9 (92.3 to 99.1)
Serotype 585.8 (78.5 to 91.4)91.3 (85.0 to 95.6)
Serotype 6A97.7 (93.5 to 99.5)99.2 (95.9 to 100.0)
Serotype 6B97.7 (93.4 to 99.5)99.3 (95.9 to 100.0)
Serotype 7F93.9 (88.4 to 97.3)99.2 (95.7 to 100.0)
Serotype 9V88.6 (82.0 to 93.5)89.5 (83.0 to 94.1)
Serotype 1498.5 (94.6 to 99.8)98.5 (94.6 to 99.8)
Serotype 18C95.5 (90.4 to 98.3)97.7 (93.5 to 99.5)
Serotype 19A99.2 (95.8 to 100.0)98.5 (94.6 to 99.8)
Serotype 19F93.0 (87.1 to 96.7)95.3 (90.2 to 98.3)
Serotype 23F86.2 (79.0 to 91.6)92.3 (86.3 to 96.2)
Statistical analysis
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -4.9 · 95% CI -12.1 to 2.0
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -3.9 · 95% CI -11.6 to 3.5
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -3.4 · 95% CI -9.6 to 2.2
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -5.5 · 95% CI -13.7 to 2.5
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -1.5 · 95% CI -5.7 to 2.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -1.6 · 95% CI -5.9 to 2.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -5.3 · 95% CI -10.8 to -0.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -0.8 · 95% CI -8.7 to 6.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: 0.0 · 95% CI -4.0 to 4.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -2.3 · 95% CI -7.6 to 2.5
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: 0.8 · 95% CI -2.8 to 4.7
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -2.4 · 95% CI -8.8 to 3.7
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -6.2 · 95% CI -14.1 to 1.5
SecondaryPercentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population

For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population
percentage of participants13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 189.7 (85.4 to 93.1)
Serotype 384.4 (79.5 to 88.6)
Serotype 484.9 (79.2 to 89.5)
Serotype 587.1 (82.2 to 91.1)
Serotype 6A84.5 (79.5 to 88.8)
Serotype 6B68.4 (62.0 to 74.2)
Serotype 7F86.1 (81.1 to 90.2)
Serotype 9V61.3 (54.8 to 67.6)
Serotype 1467.2 (61.0 to 73.0)
Serotype 18C85.6 (80.7 to 89.7)
Serotype 19A92.3 (88.3 to 95.3)
Serotype 19F88.0 (83.3 to 91.8)
Serotype 23F81.3 (75.9 to 86.0)
SecondaryPercentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 186.0 (78.8 to 91.5)93.2 (87.5 to 96.9)
Serotype 381.7 (74.0 to 87.9)87.1 (80.2 to 92.3)
Serotype 479.2 (70.0 to 86.6)90.4 (83.0 to 95.3)
Serotype 584.7 (77.0 to 90.7)89.4 (82.6 to 94.3)
Serotype 6A82.0 (74.3 to 88.3)87.1 (79.9 to 92.4)
Serotype 6B61.7 (52.2 to 70.6)74.6 (65.9 to 82.0)
Serotype 7F82.5 (74.8 to 88.7)89.8 (82.9 to 94.6)
Serotype 9V52.5 (43.1 to 61.8)70.0 (61.0 to 78.0)
Serotype 1462.4 (53.3 to 70.9)72.0 (63.3 to 79.7)
Serotype 18C80.3 (72.3 to 86.8)90.8 (84.4 to 95.1)
Serotype 19A92.7 (86.7 to 96.6)91.9 (85.7 to 96.1)
Serotype 19F86.1 (78.6 to 91.7)89.8 (83.3 to 94.5)
Serotype 23F80.0 (71.7 to 86.7)82.5 (74.8 to 88.7)
SecondaryComparison of Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group

For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Comparison of Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 186.0 (78.8 to 91.5)93.2 (87.5 to 96.9)
Serotype 381.7 (74.0 to 87.9)87.1 (80.2 to 92.3)
Serotype 479.2 (70.0 to 86.6)90.4 (83.0 to 95.3)
Serotype 584.7 (77.0 to 90.7)89.4 (82.6 to 94.3)
Serotype 6A82.0 (74.3 to 88.3)87.1 (79.9 to 92.4)
Serotype 6B61.7 (52.2 to 70.6)74.6 (65.9 to 82.0)
Serotype 7F82.5 (74.8 to 88.7)89.8 (82.9 to 94.6)
Serotype 9V52.5 (43.1 to 61.8)70.0 (61.0 to 78.0)
Serotype 1462.4 (53.3 to 70.9)72.0 (63.3 to 79.7)
Serotype 18C80.3 (72.3 to 86.8)90.8 (84.4 to 95.1)
Serotype 19A92.7 (86.7 to 96.6)91.9 (85.7 to 96.1)
Serotype 19F86.1 (78.6 to 91.7)89.8 (83.3 to 94.5)
Serotype 23F80.0 (71.7 to 86.7)82.5 (74.8 to 88.7)
Statistical analysis
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -7.2 · 95% CI -15.1 to 0.3
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -5.4 · 95% CI -14.5 to 3.5
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -11.2 · 95% CI -21.4 to -1.0
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -4.7 · 95% CI -13.5 to 3.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -5.1 · 95% CI -14.3 to 4.0
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -12.9 · 95% CI -24.6 to -0.8
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -7.3 · 95% CI -16.3 to 1.5
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -17.5 · 95% CI -29.5 to -5.0
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -9.6 · 95% CI -21.4 to 2.4
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -10.5 · 95% CI -19.3 to -1.3
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: 0.8 · 95% CI -6.2 to 7.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -3.8 · 95% CI -12.2 to 4.5
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -2.5 · 95% CI -12.5 to 7.3
SecondaryPercentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population

For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population
percentage of participants13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 188.9 (84.5 to 92.5)
Serotype 376.0 (70.4 to 81.1)
Serotype 474.6 (68.1 to 80.4)
Serotype 585.1 (79.9 to 89.3)
Serotype 6A75.4 (69.6 to 80.6)
Serotype 6B57.0 (50.4 to 63.4)
Serotype 7F81.6 (76.1 to 86.2)
Serotype 9V50.0 (43.5 to 56.5)
Serotype 1456.0 (49.6 to 62.2)
Serotype 18C77.0 (71.4 to 82.0)
Serotype 19A85.9 (80.9 to 90.0)
Serotype 19F78.8 (73.2 to 83.7)
Serotype 23F75.6 (69.7 to 80.8)
SecondaryPercentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 186.0 (78.8 to 91.5)91.7 (85.7 to 95.8)
Serotype 373.3 (64.8 to 80.6)78.8 (70.8 to 85.4)
Serotype 465.3 (55.2 to 74.5)83.7 (75.1 to 90.2)
Serotype 583.9 (76.0 to 90.0)86.2 (78.8 to 91.7)
Serotype 6A69.5 (60.8 to 77.4)81.5 (73.5 to 87.9)
Serotype 6B51.3 (41.8 to 60.7)62.3 (53.1 to 70.9)
Serotype 7F77.0 (68.6 to 84.0)86.4 (78.9 to 92.0)
Serotype 9V36.4 (27.8 to 45.8)63.3 (54.1 to 71.9)
Serotype 1452.8 (43.7 to 61.8)59.2 (50.1 to 67.9)
Serotype 18C70.9 (62.1 to 78.6)83.1 (75.5 to 89.1)
Serotype 19A85.5 (78.0 to 91.2)86.3 (79.0 to 91.8)
Serotype 19F73.0 (64.2 to 80.6)84.4 (76.9 to 90.2)
Serotype 23F71.7 (62.7 to 79.5)79.4 (71.2 to 86.1)
SecondaryComparison of Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group

For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Comparison of Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 186.0 (78.8 to 91.5)91.7 (85.7 to 95.8)
Serotype 373.3 (64.8 to 80.6)78.8 (70.8 to 85.4)
Serotype 465.3 (55.2 to 74.5)83.7 (75.1 to 90.2)
Serotype 583.9 (76.0 to 90.0)86.2 (78.8 to 91.7)
Serotype 6A69.5 (60.8 to 77.4)81.5 (73.5 to 87.9)
Serotype 6B51.3 (41.8 to 60.7)62.3 (53.1 to 70.9)
Serotype 7F77.0 (68.6 to 84.0)86.4 (78.9 to 92.0)
Serotype 9V36.4 (27.8 to 45.8)63.3 (54.1 to 71.9)
Serotype 1452.8 (43.7 to 61.8)59.2 (50.1 to 67.9)
Serotype 18C70.9 (62.1 to 78.6)83.1 (75.5 to 89.1)
Serotype 19A85.5 (78.0 to 91.2)86.3 (79.0 to 91.8)
Serotype 19F73.0 (64.2 to 80.6)84.4 (76.9 to 90.2)
Serotype 23F71.7 (62.7 to 79.5)79.4 (71.2 to 86.1)
Statistical analysis
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -5.7 · 95% CI -13.8 to 2.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -5.5 · 95% CI -15.9 to 5.0
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -18.3 · 95% CI -30.1 to -5.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -2.3 · 95% CI -11.6 to 6.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -11.9 · 95% CI -22.6 to -1.2
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -11.0 · 95% CI -23.8 to 1.9
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -9.5 · 95% CI -19.3 to 0.4
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -26.9 · 95% CI -39.0 to -14.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -6.4 · 95% CI -18.7 to 6.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -12.2 · 95% CI -22.6 to -1.7
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -0.8 · 95% CI -9.8 to 8.1
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -11.4 · 95% CI -21.7 to -1.2
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Difference in proportions: -7.7 · 95% CI -18.5 to 3.4
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Overall Population

Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · mcg/mL
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Overall Population
mcg/mL13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 16.05 (5.05 to 7.24)
Serotype 31.53 (1.36 to 1.72)
Serotype 44.57 (3.87 to 5.39)
Serotype 58.34 (7.28 to 9.56)
Serotype 6A7.93 (6.79 to 9.25)
Serotype 6B8.31 (7.08 to 9.75)
Serotype 7F10.36 (9.01 to 11.91)
Serotype 9V9.62 (8.29 to 11.16)
Serotype 1419.23 (16.47 to 22.44)
Serotype 18C13.90 (12.10 to 15.96)
Serotype 19A19.13 (16.54 to 22.13)
Serotype 19F7.77 (6.40 to 9.43)
Serotype 23F12.23 (10.34 to 14.46)
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · mcg/mL
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
mcg/mL13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 14.65 (3.65 to 5.91)7.95 (6.11 to 10.35)
Serotype 31.38 (1.17 to 1.62)1.69 (1.43 to 2.00)
Serotype 43.63 (2.88 to 4.59)5.78 (4.58 to 7.28)
Serotype 56.74 (5.62 to 8.09)10.32 (8.46 to 12.60)
Serotype 6A6.72 (5.48 to 8.24)9.37 (7.44 to 11.80)
Serotype 6B6.71 (5.42 to 8.32)10.28 (8.12 to 13.00)
Serotype 7F8.90 (7.34 to 10.80)12.10 (9.90 to 14.80)
Serotype 9V6.55 (5.32 to 8.05)14.22 (11.72 to 17.25)
Serotype 1416.73 (13.59 to 20.59)22.12 (17.59 to 27.83)
Serotype 18C10.47 (8.62 to 12.70)18.53 (15.35 to 22.37)
Serotype 19A13.51 (11.16 to 16.36)27.09 (22.07 to 33.25)
Serotype 19F4.99 (3.92 to 6.37)11.92 (8.98 to 15.82)
Serotype 23F9.38 (7.35 to 11.98)15.93 (12.75 to 19.91)
SecondaryComparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination by Age Group

Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · mcg/mL
Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination by Age Group
mcg/mL13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 14.65 (3.65 to 5.91)7.69 (5.94 to 9.96)
Serotype 31.35 (1.15 to 1.58)1.69 (1.43 to 2.00)
Serotype 43.53 (2.80 to 4.45)5.35 (4.25 to 6.75)
Serotype 56.74 (5.62 to 8.09)10.32 (8.46 to 12.60)
Serotype 6A6.72 (5.48 to 8.24)9.45 (7.51 to 11.89)
Serotype 6B6.71 (5.42 to 8.32)10.28 (8.12 to 13.00)
Serotype 7F8.90 (7.34 to 10.80)12.09 (9.92 to 14.73)
Serotype 9V6.55 (5.32 to 8.05)14.22 (11.72 to 17.25)
Serotype 1416.73 (13.59 to 20.59)22.13 (17.63 to 27.80)
Serotype 18C10.47 (8.62 to 12.70)18.48 (15.32 to 22.28)
Serotype 19A13.51 (11.16 to 16.36)27.09 (22.07 to 33.25)
Serotype 19F4.69 (3.72 to 5.91)11.21 (8.51 to 14.77)
Serotype 23F9.38 (7.35 to 11.98)15.93 (12.75 to 19.91)
Statistical analysis
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.60 · 95% CI 0.43 to 0.86Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.80 · 95% CI 0.63 to 1.00Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.66 · 95% CI 0.48 to 0.91Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.65 · 95% CI 0.50 to 0.85Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.71 · 95% CI 0.52 to 0.97Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.65 · 95% CI 0.48 to 0.90Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.74 · 95% CI 0.56 to 0.97Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.46 · 95% CI 0.35 to 0.61Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.76 · 95% CI 0.56 to 1.03Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.57 · 95% CI 0.43 to 0.74Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.50 · 95% CI 0.38 to 0.66Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.42 · 95% CI 0.29 to 0.60Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
  • 13vPnC (50 to 64 Years of Age) vs 13vPnC (≥65 Years of Age) · Ratio of geometric mean concentration: 0.59 · 95% CI 0.42 to 0.82Ratio of GMCs were calculated by back transformation of the mean difference between age groups on the logarithmic scale.
SecondaryImmunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Overall Population

Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · fold rise
Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Overall Population
fold rise13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Serotype 111.38 (9.65 to 13.43)
Serotype 32.89 (2.60 to 3.22)
Serotype 415.89 (13.45 to 18.77)
Serotype 54.15 (3.64 to 4.74)
Serotype 6A4.23 (3.69 to 4.84)
Serotype 6B4.32 (3.76 to 4.96)
Serotype 7F11.59 (9.96 to 13.49)
Serotype 9V8.56 (7.43 to 9.87)
Serotype 146.79 (5.78 to 7.98)
Serotype 18C12.94 (11.01 to 15.21)
Serotype 19A7.36 (6.39 to 8.48)
Serotype 19F6.03 (5.10 to 7.14)
Serotype 23F7.80 (6.70 to 9.07)
SecondaryImmunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · fold rise
Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
fold rise13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Serotype 18.86 (7.08 to 11.09)14.77 (11.65 to 18.72)
Serotype 32.40 (2.07 to 2.79)3.47 (2.98 to 4.05)
Serotype 411.33 (9.06 to 14.19)22.44 (17.75 to 28.38)
Serotype 53.23 (2.70 to 3.85)5.34 (4.42 to 6.46)
Serotype 6A3.32 (2.80 to 3.94)5.39 (4.38 to 6.64)
Serotype 6B3.26 (2.72 to 3.92)5.71 (4.68 to 6.97)
Serotype 7F9.10 (7.39 to 11.22)14.88 (12.00 to 18.45)
Serotype 9V5.76 (4.77 to 6.95)12.80 (10.56 to 15.51)
Serotype 145.93 (4.78 to 7.35)7.80 (6.13 to 9.91)
Serotype 18C9.92 (7.99 to 12.31)16.96 (13.42 to 21.43)
Serotype 19A5.12 (4.30 to 6.10)10.57 (8.60 to 12.99)
Serotype 19F3.80 (3.07 to 4.71)9.43 (7.45 to 11.94)
Serotype 23F6.26 (5.02 to 7.80)9.71 (7.91 to 11.91)
SecondaryPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Overall Population

Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).

Time frame:
Day 1 through 14
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Overall Population
percentage of participants13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Redness: any14.4
Redness: mild8.7
Redness: moderate9.3
Redness: severe0.5
Swelling: any11.5
Swelling: mild7.2
Swelling: moderate5.8
Swelling: severe0.5
Pain: any48.3
Pain: mild46.1
Pain: moderate9.6
Pain: severe0.5
Limitation of arm movement: any53.2
Limitation of arm movement: mild52.2
Limitation of arm movement: moderate4.4
Limitation of arm movement: severe1.5
SecondaryPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).

Time frame:
Day 1 through 14
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Redness: any7.120.9
Redness: mild7.110.0
Redness: moderate1.016.7
Redness: severe0.00.9
Swelling: any8.114.7
Swelling: mild7.17.3
Swelling: moderate2.09.3
Swelling: severe0.00.9
Pain: any52.244.3
Pain: mild49.642.6
Pain: moderate8.910.3
Pain: severe1.00.0
Limitation of arm movement: any53.053.4
Limitation of arm movement: mild51.852.5
Limitation of arm movement: moderate5.13.7
Limitation of arm movement: severe2.10.9
SecondaryPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Overall Population

Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.

Time frame:
Day 1 through 14
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Overall Population
percentage of participants13vPnC Overall Population (50 to 64 and ≥65 Years of Age)
Fever: any ≥37.5 degrees C3.4
Fever: mild ≥37.5 but <38.5 degrees C2.9
Fever: moderate ≥38.5 but <39 degrees C0.5
Fatigue31.2
Headache19.9
Chills12.7
Rash10.7
Vomiting2.0
Decreased appetite12.6
New muscle pain31.8
Any aggravated muscle pain10.1
New joint pain11.0
Any aggravated joint pain6.3
SecondaryPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years

Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.

Time frame:
Day 1 through 14
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
percentage of participants13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Fever any ≥37.5 degrees C3.13.7
Fever: mild ≥37.5 but <38.5 degrees C2.03.7
Fever: moderate ≥38.5 but <39 degrees C1.00.0
Fatigue38.824.1
Headache26.014.4
Chills14.910.8
Rash8.213.1
Vomiting3.10.9
Decreased appetite16.29.3
New muscle pain34.329.5
Any aggravated muscle pain11.29.1
New joint pain10.011.8
Any aggravated joint pain7.15.5

Adverse events

Collected over Adverse events reported via the electronic-diary were collected within 14 days of vaccination; all other adverse events were documented from the signing of the informed consent form up to approximately one month after vaccination (up to Day 43). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC (50 to 64 Years of Age)—1/134 (0.7%)120/134 (89.6%)
13vPnC (≥65 Years of Age)—1/136 (0.7%)118/136 (86.8%)
Most frequent serious events
Most frequent serious events
Event13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Subarachnoid haemorrhageNervous system disorders1/1340/136
Cardiac failure congestiveCardiac disorders0/1341/136
Most frequent other events
Showing 10 of 60
Most frequent other events
Event13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)
Limitation of arm movement: anySkin and subcutaneous tissue disorders61/11563/118
Limitation of arm movement: mildSkin and subcutaneous tissue disorders59/11462/118
Pain: anySkin and subcutaneous tissue disorders60/11551/115
Pain: mildSkin and subcutaneous tissue disorders56/11349/115
Injection site movement impairmentGeneral disorders48/13454/136
Injection site painGeneral disorders53/13452/136
FatigueGeneral disorders40/10327/112
New muscle painGeneral disorders36/10533/112
HeadacheGeneral disorders26/10016/111
Redness: anySkin and subcutaneous tissue disorders7/9823/110

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)Total
Mean57.5 ± 4.070.5 ± 4.464.0 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC (50 to 64 Years of Age)13vPnC (≥65 Years of Age)Total
Female7670146
Male5864122
08

Study locations

2 sites
  • Fukuoka-shi, Fukuoka 812-0025, Japan
  • Sumida-ku, Tokyo 130-0004, Japan
09

References and documents

Publications

  • Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, Belanger T, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged >/=50 years. An open-label trial. Hum Vaccin Immunother. 2014;10(7):1850-8. doi: 10.4161/hv.28633. PubMed 25424792 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 3 years 11 months after primary completion. A results delay was requested in Jan 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2007
First posted
Nov 22, 2007
Start
Oct 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results delay requested
Jan 21, 2009
Results first posted
Nov 11, 2011
Last update
Nov 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00562354
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 22, 2007
Start date
Oct 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Nov 11, 2011
Last update
Nov 11, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion